Patents Assigned to American Infertility of New York
-
Patent number: 10884003Abstract: Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.Type: GrantFiled: January 7, 2019Date of Patent: January 5, 2021Assignees: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Publication number: 20200030342Abstract: A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrosterone (DHEA) supplementation to be taken in 25 mg dosages daily once, twice, thrice or four times over a period of time of four to six weeks. By the end of the period of time, the FSFI baselines of the premenopausal women improves by at least seven percent, serum androgen levels of the premenopausal women increase and follicle-stimulating hormone (FSH) levels of the premenopausal women decrease.Type: ApplicationFiled: July 27, 2018Publication date: January 30, 2020Applicants: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Publication number: 20190195895Abstract: Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.Type: ApplicationFiled: January 7, 2019Publication date: June 27, 2019Applicants: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Patent number: 10175252Abstract: Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.Type: GrantFiled: February 4, 2016Date of Patent: January 8, 2019Assignee: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Patent number: 9974834Abstract: A method of diagnosing a subject's percentage of probability of retrieval of oocytes based on an age of the subject by selecting the percentage that matches the subject's AMR level in accord with plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes and administering AMR to the subject, as warranted, to increase the AMR level to attain a desired percentage of probability of retrieval of oocytes based upon the age of the subject and in accord with a matching percentage for the increased AMR level from plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes.Type: GrantFiled: March 3, 2016Date of Patent: May 22, 2018Assignee: AMERICAN INFERTILITY OF NEW YORK, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Publication number: 20170252404Abstract: A method of diagnosing a subject's percentage of probability of retrieval of oocytes based on an age of the subject by selecting the percentage that matches the subject's AMR level in accord with plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes and administering AMR to the subject, as warranted, to increase the AMR level to attain a desired percentage of probability of retrieval of oocytes based upon the age of the subject and in accord with a matching percentage for the increased AMR level from plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes.Type: ApplicationFiled: March 3, 2016Publication date: September 7, 2017Applicants: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Publication number: 20170227554Abstract: Method of diagnosis of IVF viability. The method includes ascertaining a subject's AMH level from testing and then selecting one pregnancy or live birth prognosis category that applies to the ascertained AMH level by matching the ascertained AMH level with an applicable one of a plurality of ranges of AMH levels pertaining to an age of the subject. The matching indicates the prognosis category that applies, i.e., (that is, good, intermediate or poor. In view of the diagnosis, a method of administration of AMH may be pursued to increase probability of pregnancy or live birth chances. Alternatively, the administration of AMH may be at AMH levels that will terminate pregnancy or increase the chance of miscarriage.Type: ApplicationFiled: February 4, 2016Publication date: August 10, 2017Applicants: American Infertility of New York, P.C.Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
-
Patent number: 8501719Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.Type: GrantFiled: October 30, 2009Date of Patent: August 6, 2013Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Patent number: 8501718Abstract: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.Type: GrantFiled: October 7, 2009Date of Patent: August 6, 2013Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Patent number: 8067400Abstract: A method of improving cumulative embryo score may comprise administering an androgen to a human female for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. A method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. A method of normalizing ovarian DHEA may include administering an androgen for at least about four consecutive months. A method of decreasing the time to pregnancy and increasing the rate of pregnancy by administering an androgen for at least about two months. A method of decreasing miscarriage rates may comprise administering an androgen for at least about two months to a female. Moreover, a method of decreasing aneuploidy rates in human embryos may comprise administering an androgen to a female for at least about two months.Type: GrantFiled: May 20, 2008Date of Patent: November 29, 2011Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Publication number: 20100113407Abstract: The present invention is directed to a method of using dehydroepiandrosterone (DHEA) to treat a human female with diminished ovarian reserve. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of DHEA per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of DHEA per day to the female for at least four months.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Applicant: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Patent number: 7615544Abstract: A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a human female per day. Moreover, a method of increasing the quantity of fertilized oocytes in one cycle of in vitro fertilization may comprise administering an androgen to a human female for at least about four consecutive months, harvesting and fertilizing the oocytes. Furthermore, a method of increasing the quantity of day 3 embryos from one cycle of in vitro fertilization may comprise administering an androgen for at least about four consecutive months, harvesting and fertilizing the oocytes and forming day 3 embryos. A method of normalizing ovarian DHEA also may include administering an androgen for at least about four consecutive months.Type: GrantFiled: November 8, 2005Date of Patent: November 10, 2009Assignee: American Infertility of New YorkInventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben